MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

106.2

-0.66%↓

WBA

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

106.2

-0.66%↓

WBA

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

106.2

-0.66%↓

WBA

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

106.2

-0.66%↓

WBA

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

106.2

-0.66%↓

WBA

-0.18%↓

CHE

555.98

+1.76%↑

Начало・Списък с акции・Arvinas Inc

Arvinas Inc

Затворен

СекторЗдравеопазване

9.07 -0.87

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

8.86

Максимум

9.07

Ключови измерители
By Trading Economics
Приходи	4.1M -45M
Продажби	-43M 59M
EPS	-0.63
Марж на печалбата	-76.182
Служители	430
EBITDA	3.7M -57M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+275.03% upside

Дивиденти
By Dow Jones
Следващи печалби	6.05.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	602M
Предишно отваряне	9.94
Предишно затваряне	9.07

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

8.6 / 9.25 Подкрепа & съпротива

Arvinas Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

27.04.2025 г., 23:55 ч. UTC

Пазарно говорене

Oil Edges Higher Amid Hopes for Easing U.S.-China Trade Tensions -- Market Talk

27.04.2025 г., 23:47 ч. UTC

Пазарно говорене

Gold Falls Amid Dollar Strength, Signs of Easing U.S.-China Trade Tensions -- Market Talk

27.04.2025 г., 23:42 ч. UTC

Пазарно говорене

Nikkei May Rise as Fears About U.S.-China Tensions Ebb -- Market Talk

27.04.2025 г., 23:12 ч. UTC

Печалби

Sinopharm Group 1Q Rev CNY141.66B Vs. CNY147.27B >1099.HK

27.04.2025 г., 23:12 ч. UTC

Печалби

Sinopharm Group 1Q Net CNY1.46B Vs. Net CNY1.42B >1099.HK

27.04.2025 г., 20:41 ч. UTC

Печалби

Pharmaron Beijing 1Q Net CNY305.58M Vs. Net CNY230.56M >300759.SZ

27.04.2025 г., 20:41 ч. UTC

Печалби

Pharmaron Beijing: Higher Contributions From Laboratory Services Among Factors Supporting Results> 300759.SZ

27.04.2025 г., 20:41 ч. UTC

Печалби

Pharmaron Beijing 1Q Rev CNY3.10B Vs. CNY2.67B >300759.SZ

27.04.2025 г., 18:41 ч. UTC

Топ новини

Bessent Doesn't Know If Trump and Xi Have Talked on Trade -- Barrons.com

27.04.2025 г., 11:00 ч. UTC

Топ новини

Wall Street's New Tariff Safe Haven: High-Tax Biotech Stocks -- Heard on the Street -- WSJ

27.04.2025 г., 05:41 ч. UTC

Печалби

China Everbright Bank 1Q Net CNY12.46B Vs. Net CNY12.43B >601818.SH

27.04.2025 г., 05:41 ч. UTC

Печалби

China Everbright Bank: Lower Net Interest Income Weighed on Operating Income>601818.SH

27.04.2025 г., 05:41 ч. UTC

Печалби

China Everbright Bank 1Q Operating Income CNY33.10B Vs. CNY34.49B>601818.SH

27.04.2025 г., 05:41 ч. UTC

Печалби

China Everbright Bank 1Q Impairment Loss on Credit Assets Was CNY8.49B; Down 15.6% on Year>601818.SH

27.04.2025 г., 05:41 ч. UTC

Печалби

China Everbright Bank 1Q Operating Expenses Was CNY9.15B; Down 3.2%>601818.SH

27.04.2025 г., 05:41 ч. UTC

Печалби

China Everbright Bank 1Q Net Interst Income Was CNY22.54B; Down 6.8% on Year>601818.SH

27.04.2025 г., 05:34 ч. UTC

Печалби

Chongqing Rural Commercial Bank: 1Q Results Supported by Higher Net Interest Income>3618.HK

27.04.2025 г., 05:34 ч. UTC

Печалби

Chongqing Rural Commercial Bank 1Q Operating Income CNY7.22B Vs. CNY7.13B>3618.HK

27.04.2025 г., 05:34 ч. UTC

Печалби

Chongqing Rural Commercial Bank 1Q Net CNY3.75B Vs. Net CNY3.52B >3618.HK

27.04.2025 г., 05:29 ч. UTC

Печалби

China Shenhua Energy: Results Weighed by Fall in Selling Prices of Coal >1088.HK

27.04.2025 г., 05:29 ч. UTC

Печалби

China Shenhua Energy 1Q Net CNY13.37B Vs. Net CNY17.76B >1088.HK

27.04.2025 г., 05:29 ч. UTC

Печалби

China Shenhua Energy 1Q Rev CNY69.59B Vs. CNY87.65B >1088.HK

27.04.2025 г., 05:29 ч. UTC

Печалби

China Shenhua Energy: Lower Revenue From Electricity Sales Also Hurt Results >1088.HK

27.04.2025 г., 05:21 ч. UTC

Печалби

CMOC Group 1Q Net CNY3.95B Vs. Net CNY2.07B >3993.HK

27.04.2025 г., 05:21 ч. UTC

Печалби

CMOC Group: Cost Cuts Also Among Factors that Boosted 1Q Net >3993.HK

27.04.2025 г., 05:21 ч. UTC

Печалби

CMOC Group 1Q Rev CNY46.01B Vs. CNY46.12B >3993.HK

27.04.2025 г., 05:21 ч. UTC

Печалби

CMOC Group: Increase in Prices of Copper, Cobalt Supported Results>3993.HK

27.04.2025 г., 03:00 ч. UTC

Топ новини

Chinese Manufacturers Are Scouring the World for New Buyers -- WSJ

27.04.2025 г., 00:30 ч. UTC

Топ новини

Meta's 'Digital Companions' Will Talk Sex With Users -- Even Children -- WSJ

27.04.2025 г., 00:30 ч. UTC

Топ новини

Meta's 'Digital Companions' Will Talk Sex With Users -- Even Children -- WSJ -2-

Сравнение с други в отрасъла

Ценова промяна

Arvinas Inc Прогноза

Ценова цел

By TipRanks

275.03% нагоре

12-месечна прогноза

Среден 33.94 USD 275.03%

Висок 81 USD

Нисък 10 USD

Според 20 анализатори от Wall Street, предложили 12-месечна ценова цел за Arvinas Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

20 ratings

Купи

Задържане

Продай

Според 20 анализатори, дали борсови рейтинги на Arvinas Inc през последните 3 месеца.

Техническа оценка

By Trading Central

8.6 / 9.25Подкрепа & съпротива

Bullish events outweigh bearish events.

The bullish and bearish events are balanced.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Arvinas Inc

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.